EXHIBIT 4.1
SIXTH AMENDED AND RESTATED
REGISTRATION RIGHTS AGREEMENT
DATED AS OF OCTOBER 16, 2000
LXN CORPORATION
SIXTH AMENDED AND RESTATED
REGISTRATION RIGHTS AGREEMENT
This Sixth Amended And Restated Registration Rights Agreement (the
"Agreement") is made as of October 16, 2000 by and among LXN Corporation, a
Delaware corporation (the "Company"), the purchasers of shares of Series A
Preferred Stock of the Company listed on Exhibit A attached hereto (the "Series
A Purchasers") pursuant to a Series A Preferred Stock Purchase Agreement dated
February 7, 1994 (the "Series A Purchase Agreement"), the purchasers of shares
of Series B Preferred Stock of the Company listed on Exhibit B attached hereto
(the "Series B Purchasers") pursuant to a Series B Preferred Stock Purchase
Agreement dated May 26, 1995 (the "Series B Purchase Agreement"), the purchasers
of shares of Series C Preferred Stock of the Company listed on Exhibit C
attached hereto (the "Series C Purchasers") pursuant to a Series C Preferred
Stock Purchase Agreement dated July 12, 1996 (the "Series C Purchase
Agreement"), the purchasers of Series D Preferred Stock of the Company listed on
Exhibit D attached hereto (the "Series D Purchasers") pursuant to a Series D
Preferred Stock Purchase Agreement dated September 5, 1997, October 31, 1997,
and January 30, 1998 (the "Series D Purchase Agreement"), purchasers of Series E
Preferred Stock of the Company listed on Exhibit E attached hereto (the "Series
E Purchasers") pursuant to a Series E Preferred Stock Purchase Agreement dated
March 8, 2000 (the "Series E Purchase Agreement") and purchasers of Series F
Preferred Stock of the Company listed on Exhibit F attached hereto (the "Series
F Purchasers") pursuant to a Series F Preferred Stock Purchase Agreement of even
date herewith (the "Series F Purchase Agreement") (the Series A Purchasers,
Series B Purchasers, Series C Purchasers, Series D Purchasers, Series E
Purchasers and Series F Purchasers, collectively the "Purchasers").
Recitals
A. The Company proposes to sell up to eight hundred fifty seven thousand
one hundred forty three (857,143) shares of its Series F Preferred Stock
("Series F Preferred") pursuant to the Series F Purchase Agreement.
B. Pursuant to the Series F Purchase Agreement, the Series F Purchasers
have agreed to become parties to this Agreement on the terms set forth herein.
C. In order to induce the Series F Purchasers to purchase the Series F
Preferred, the Series A Purchasers, Series B Purchasers, Series C Purchasers,
Series D Purchasers and Series E Purchasers have agreed to waive with respect to
the issuance, purchase and sale of the Series F Preferred any and all rights of
first refusal enjoyed by the Series A Purchasers, Series B Purchasers, Series C
Purchasers, Series D Purchasers and Series E Purchasers pursuant to the Fifth
Amended and Restated Registration Rights Agreement dated March 8, 1999, by and
among the Company, the Series A Purchasers, the Series B Purchasers, the Series
C Purchasers, the Series D Purchasers and the Series E Purchasers (the "1999
Registration Rights Agreement").
1
D. In order to induce the Series F Purchasers to purchase the Series F
Preferred, the Series A Purchasers, Series B Purchasers, Series C Purchasers,
Series D Purchasers, Series E Purchasers and the Company have agreed that the
1999 Registration Rights Agreement is to be terminated and superseded in all
respects by this Agreement.
Now, Therefore, in consideration of the mutual promises and covenants
hereinafter set forth, all parties hereto agree as follows:
1. Waiver Of Right Of First Refusal; Termination Of 1999 Registration Rights
Agreement. The Series A Purchasers, Series B Purchasers, Series C Purchasers,
Series D Purchasers and Series E Purchasers hereby waive with respect to the
issuance, purchase and sale of the Series F Preferred any and all rights of
first refusal (and any rights to notice in connection therewith) held by the
Series A Purchasers, Series B Purchasers, Series C Purchasers, Series D
Purchasers and Series E Purchasers pursuant to Section 8 of the 1999
Registration Rights Agreement. The 1999 Registration Rights Agreement is
herewith terminated and superseded in all respects by this Agreement, pursuant
to Section 11 thereof, and is of no further force or effect.
2. Certain Definitions. All capitalized terms used and not otherwise defined
herein shall have the meanings given them in the Series E Purchase Agreement.
As used in this Agreement, the following terms shall have the following
respective meanings:
"Commission" shall mean the Securities and Exchange Commission or any other
federal agency at the time administering the Securities Act.
"Conversion Stock" means the Common Stock issued or issuable pursuant to
conversion of the Preferred Stock.
"Holder" shall mean (i) any of the Series A Purchasers holding Registrable
Securities, (ii) any of the Series B Purchasers holding Registrable Securities,
(iii) any of the Series C Purchasers holding Registrable Securities, (iv) any of
the Series D Purchasers holding Registrable Securities, (v) any of the Series E
Purchasers holding Registrable Securities, (vi) any of the Series F Purchasers
holding Registrable Securities and (vii) any person holding Registrable
Securities to whom the rights under this Agreement have been transferred in
accordance with Section 6.10 hereof.
"Initiating Holders" shall mean any Holders who in the aggregate hold not
less than fifty percent (50%) of the Registrable Securities.
"Preferred Stock" shall mean, collectively, the Series A Preferred Stock
issued pursuant to the Series A Purchase Agreement, the Series B Preferred Stock
issued pursuant to the Series B Purchase Agreement, the Series C Preferred Stock
issued pursuant to the Series C Purchase Agreement, the Series D Preferred Stock
issued pursuant to the Series D Purchase Agreement or pursuant to the exercise
of the outstanding warrant to purchase such shares of Series D Preferred Stock,
the Series E Preferred Stock issued pursuant to the Series E Purchase Agreement
or pursuant to the exercise of the outstanding warrants to purchase such shares
of Series E Preferred Stock and the Series F Preferred Stock issued pursuant to
the Series F Purchase Agreement.
2
"Purchase Agreements" shall mean the Series A Purchase Agreement, the
Series B Purchase Agreement, the Series C Purchase Agreement, the Series D
Purchase Agreement, the Series E Purchase Agreement and the Series F Purchase
Agreement.
"Purchaser" or "Purchasers" shall mean, collectively, the Series A
Purchasers, the Series B Purchasers, the Series C Purchasers, the Series D
Purchasers, the Series E Purchasers and the Series F Purchasers.
"Registrable Securities" means the Conversion Stock and any Common Stock of
the Company issued or issuable in respect of the Conversion Stock upon any stock
split, stock dividend, recapitalization, or similar event, or any Common Stock
otherwise issuable with respect to the Conversion Stock; provided, however, that
shares of Conversion Stock or other securities shall only be treated as
Registrable Securities if and so long as they have not been sold to or through a
broker or dealer or underwriter in a public distribution or a public securities
transaction.
The terms "register," "registered" and "registration" refer to a
registration effected by preparing and filing a registration statement in
compliance with the Securities Act, and the declaration or ordering of the
effectiveness of such registration statement.
"Registration Expenses" shall mean all expenses, except as stated in
Section 6.5 hereof, incurred by the Company in complying with Sections 6.1, 6.2
and 6.3 hereof, including, without limitation, all registration, qualification
and filing fees, printing expenses, escrow fees, fees and disbursements of
counsel for the Company, blue sky fees and expenses, the expense of any special
audits incident to or required by any such registration (but excluding the
compensation of regular employees of the Company which shall be paid in any
event by the Company) and the reasonable fees and disbursements of one counsel
for all Holders.
"Restricted Securities" shall mean the securities of the Company required
to bear the legend set forth in Section 4 hereof.
"Securities Act" shall mean the Securities Act of 1933, as amended, or any
similar federal statute and the rules and regulations of the Commission
thereunder, all as the same shall be in effect at the time.
"Selling Expenses" shall mean all underwriting discounts, selling
commissions and stock transfer taxes applicable if to the securities registered
by the Holders and, except as set forth under "Registration Expenses", all
reasonable fees and disbursements of separate counsel for any Holder.
3. Restrictions On Transferability. The Conversion Stock and any other
securities issued in respect of the Conversion Stock upon any stock split, stock
dividend, recapitalization, merger, consolidation or similar event, shall not be
sold, assigned, transferred or pledged except upon the conditions specified in
this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. Each Holder will cause any proposed
purchaser, assignee, transferee, or pledgee of any such shares held by the
Holder to agree to take and hold such securities subject to the provisions and
upon the conditions specified in this Agreement.
3
4. Restrictive Legend. Each certificate representing: (i) the Conversion
Stock and (ii) any other securities issued in respect of the Conversion Stock
upon any stock split, stock dividend, recapitalization, merger, consolidation or
similar event, shall (unless otherwise permitted by the provisions of Section 5
below) be stamped or otherwise imprinted with a legend in substantially the
following form (in addition to any legend required under applicable state
securities laws):
THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF.
SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION
UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO IT
STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND
PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. COPIES OF THE AGREEMENTS COVERING
THE PURCHASE OF THESE SHARES AND RESTRICTING THEIR TRANSFER MAY BE OBTAINED AT
NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO
THE SECRETARY OF THE COMPANY AT THE PRINCIPAL EXECUTIVE OFFICES OF THE COMPANY.
Each Holder consents to the Company's making a notation on its records and
giving instructions to any transfer agent for the Preferred Stock or the Common
Stock in order to implement the restrictions on transfer established in this
Agreement.
5. Notice Of Proposed Transfers. The holder of each certificate representing
Restricted Securities by acceptance thereof agrees to comply in all respects
with the provisions of this Section 5. Prior to any proposed sale, assignment,
transfer or pledge of any Restricted Securities (other than: (i) a transfer not
involving a change in beneficial ownership, or (ii) in transactions involving
the distribution without consideration of Restricted Securities by the Purchaser
to any of its partners or members, or retired partners or members), or to the
estate of any of its partners or members or retired partners or members, unless
there is in effect a registration statement under the Securities Act covering
the proposed transfer, the holder thereof shall give written notice to the
Company of such holder's intention to effect such transfer, sale, assignment or
pledge. Each such notice shall describe the manner and circumstances of the
proposed transfer, sale, assignment or pledge in sufficient detail, and shall be
accompanied, at such holder's expense by either: (i) an unqualified written
opinion of legal counsel who shall be, and whose legal opinion shall be,
reasonably satisfactory to the Company addressed to the Company, to the effect
that the proposed transfer of the Restricted Securities may be effected without
registration under the Securities Act, or (ii) a "no action" letter from the
Commission to the effect that the transfer of such securities without
registration will not result in a recommendation by the staff of the Commission
that action be taken with respect thereto, whereupon the holder of such
Restricted Securities shall be entitled to transfer such Restricted Securities
in accordance with the terms of the notice delivered by the holder to the
Company. Notwithstanding the foregoing, it is agreed that the Company will not
request an opinion of counsel for the holder for transactions made in reliance
on Rule 144 under the Securities Act except in unusual circumstances, the
existence of which shall be determined in good faith by the
4
Board of Directors of the Company. Each certificate evidencing the Restricted
Securities transferred as above provided shall bear, except if such transfer is
made pursuant to Rule 144, the appropriate restrictive legend set forth in
Section 4 above, except that such certificate shall not bear such restrictive
legend if in the opinion of counsel for such holder and the Company such legend
is not required in order to establish compliance with any provision of the
Securities Act.
6. Registration.
6.1 Requested Registration.
(a) Request for Registration. In case the Company shall receive from
Initiating Holders a written request that the Company effect any registration,
qualification or compliance with respect to shares of the Company having
registration rights, and the anticipated aggregate offering price, net of
underwriting discounts and commissions, would exceed seven million five hundred
thousand dollars ($7,500,000), the Company will:
(i) promptly give written notice of the proposed registration,
qualification or compliance to all other Holders; and
(ii) as soon as practicable, use its best efforts to effect such
registration, qualification or compliance (including, without limitation,
appropriate qualification under applicable blue sky or other state securities
laws and appropriate compliance with applicable regulations issued under the
Securities Act and any other governmental requirements or regulations) as may be
so requested and as would permit or facilitate the sale and distribution of all
or such portion of such Registrable Secu-rities as are specified in such
request, together with all or such portion of the Registrable Securities of any
Holder or Holders joining in such request as are specified in a written request
received by the Company within fifteen (15) days after receipt of such written
notice from the Company;
Provided, however, that the Company shall not be obligated to take any
action to effect any such registration, qualification or compliance pursuant to
this Section 6.1:
(1) In any particular jurisdiction in which the Company
would be required to execute a general consent to service of process in
effecting such registration, qualification or compliance unless the Company is
already subject to service in such jurisdiction and except as may be required by
the Securities Act;
(2) Prior to twelve (12) months after the closing of the
Company's first registered public offering of its stock, or prior to October 1,
2001, whichever is earlier;
(3) Following notice to the Holders by the Company, during
the period starting with the date sixty (60) days prior to the Company's
estimated date of filing of, and ending on the date six (6) months immediately
following the effective date of, any registration statement pertaining to
securities of the Company (other than a registration of securities in a Rule 145
transaction or with respect to an employee benefit plan), provided that the
Company is actively employing in good faith all reasonable efforts to cause such
registration statement to become effective;
5
(4) After the Company has effected two such registrations
pursuant to this subparagraph 6.1(a), and such registrations have been declared
or ordered effective;
(5) If the Company shall furnish to such Initiating Holders
a certificate signed by the Chief Executive Officer of the Company stating that
in the good faith judgment of the Chief Executive Officer it would be seriously
detrimental to the Company or its stockholders for a registration statement to
be filed in the near future, then the Company's obligation to use its best
efforts to register, qualify or comply under this Section 6.1 shall be deferred
for a period not to exceed ninety (90) days from the date of receipt of written
request from the Initiating Holders, provided that the Company may not exercise
this deferral right more than once per twelve (12) month period; or
(6) If such registration, qualification or compliance is
not proposed to be part of a firm commitment underwritten public offering with
underwriters reasonably acceptable to the Company.
Subject to the foregoing clauses (A) through (F), the Company shall file a
registration statement covering the Registrable Securities so requested to be
registered as soon as practicable after receipt of the request or requests of
the Initiating Holders.
(b) Underwriting. In the event of an underwritten registration
pursuant to Section 6.1, the Company shall advise the Holders as part of the
notice given pursuant to Section 6.1(a)(i) that the right of any Holder to
registration pursuant to Section 6.1 shall be conditioned upon such Holder's
participation in the underwriting arrangements required by this Section 6.1, and
the inclusion of such Holder's Registrable Securities in the underwriting to the
extent requested shall be limited to the extent provided herein.
The Company shall (together with all Holders proposing to distribute their
securities through such underwriting) enter into an underwriting agreement in
customary form with the managing underwriter selected for such underwriting by a
majority in interest of the Initiating Holders, but subject to the Company's
reasonable approval. Notwithstanding any other provision of this Section 6.1,
if the managing underwriter advises the Initiating Holders in writing that
marketing factors require a limitation of the number of shares to be
underwritten, then the Company shall so advise all Holders of Registrable
Securities, and the number of shares of Registrable Securities that may be
included in the registration and underwriting shall be allocated among all
Holders in proportion, as nearly as practicable, to the respective amounts of
Registrable Securities held by such Holders at the time of filing the
registration statement. Neither the Company nor any other holders of
Registration Rights may participate in the proposed offering if any Holders have
been cut back pursuant to this Section 6.1(b). No Registrable Securities
excluded from the underwriting by reason of the underwriter's marketing
limitation shall be included in such registration. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the
nearest 100 shares.
If any Holder of Registrable Securities disapproves of the terms of the
underwriting, such person may elect to withdraw therefrom by written notice to
the Company, the managing
6
underwriter and the Initiating Holders. The Registrable Securities and/or other
securities so withdrawn shall also be withdrawn from registration, and such
Registrable Securities shall continue to be subject to the terms of this
Agreement including Section 7 hereof.
6.2 Company Registration.
(a) Notice of Registration. If at any time or from time to time the
Company shall determine to register any of its equity securities, either for its
own account or the account of a security holder or holders, other than: (i) a
registration relating solely to employee benefit plans, (ii) a registration
relating solely to a Rule 145 transaction, or (iii) a registration in which the
only equity security being registered is Common Stock issuable upon conversion
of convertible debt securities which are also being registered, the Company
will:
(i) promptly give to each Holder written notice thereof (other
than the initial public offering of the Company's securities, if all Holders are
to be excluded therefrom pursuant to Section 6.2(b) below); and
(ii) include in such registration (and any related qualification
under blue sky laws or other compliance), and in any underwriting involved
therein, all the Registrable Securities specified in a written request or
requests, made within ten (10) days after receipt of such written notice from
the Company, by any Holder.
(b) Underwriting. If the registration of which the Company gives
notice is for a registered public offering involving an underwriting, the
Company shall so advise the Holders as a part of the written notice given
pursuant to Section 6.2(a)(i). In such event the right of any Holder to
registration pursuant to this Section 6.2 shall be conditioned upon such
Holder's participation in such underwriting, and the inclusion of Registrable
Securities in the underwriting shall be limited to the extent provided herein.
All Holders proposing to distribute their securities through such
underwriting shall (together with the Company and the other holders distributing
their securities through such underwriting) enter into an underwriting agreement
in customary form with the managing underwriter selected for such underwriting
by the Company. Notwithstanding any other provision of this Section 6.2, if the
managing underwriter determines that marketing factors require a limitation of
the number of shares to be underwritten, the managing underwriter may exclude
some or all of the Registrable Securities, or securities of other holders of
registration rights other than persons exercising demand registration rights,
from such registration; provided, however, that the aggregate amount of
Registrable Securities of the holders to be included in the offering shall not
be reduced below twenty percent (20%) of the total amount of securities included
in such offering, unless such offering is the initial public offering of the
Company's securities in which case the Holders may be excluded if the
underwriters make the determination described above and no other Holder's
securities are included. The Company shall so advise all Holders and other
holders distributing their securities through such underwriting, and the number
of shares of Registrable Securities, or securities of other holders of
registration rights other than persons exercising demand registration rights,
that may be included in the registration and underwriting shall be allocated
among all the Holders and such other holders of securities not exercising demand
registration rights in proportion, as nearly as practicable, to the respective
7
amounts of Registrable Securities or securities held by such Holder or holder at
the time of filing the Registration Statement. To facilitate the allocation of
shares in accordance with the above provisions, the Company may round the number
of shares allocated to any Holder or holder to the nearest 100 shares.
If any Holder or holder disapproves of the terms of any such underwriting,
he or she may elect to withdraw therefrom by written notice to the Company and
the managing underwriter. Any securities excluded or withdrawn from such
underwriting shall be withdrawn from such registration, and shall continue to be
subject to the terms of this Agreement including Section 7 hereof.
(c) Right to Terminate Registration. The Company shall have the
right to terminate or withdraw any registration initiated by it under this
Section 6.2 prior to the effectiveness of such registration whether or not any
Holder has elected to include securities in such registration.
6.3 Registration on Form S-3.
(a) If any Holder or Holders request that the Company file a
registration statement on Form S-3 (or any successor form to Form S-3) for a
public offering of shares of the Registrable Securities the reasonably
anticipated aggregate price to the public of which, net of underwriting
discounts and commissions, would exceed five hundred thousand dollars
($500,000), and the Company is a registrant entitled to use Form S-3 to register
the Registrable Securities for such an offering, the Company shall use its best
efforts to cause such Registrable Securities to be registered for the offering
on such form and to cause such Registrable Securities to be qualified in such
jurisdictions as such Holder or Holders may reasonably request; provided,
however, that the Company shall not be required to effect more than one
registration pursuant to Sections 6.1 or this Section 6.3 in any six (6) month
period. The Company shall inform other Holders of the proposed registration and
offer them the opportunity to participate. In the event the registration is
proposed to be part of a firm commitment underwritten public offering, the
substantive provisions of Section 6.1(b) shall be applicable to each such
registration initiated under this Section 6.3. Such registrations on Form S-3
shall be subject to the limitations, requirements and restrictions of this
Section 6.3. The Company may include other shares of Common Stock in any of the
registrations provided for in this Section 6.3, provided that such inclusion
will not interfere with the marketing of the Registrable Securities to be
registered by the Holders.
(b) Notwithstanding the foregoing, the Company shall not be obligated
to take any action pursuant to this Section 6.3:
(i) in any particular jurisdiction in which the Company would be
required to execute a general consent to service of process in effecting such
registration, qualification or compliance unless the Company is already subject
to service in such jurisdiction and except as may be required by the Securities
Act;
(ii) following the period starting with the date sixty (60) days
prior to the Company's estimated date of filing of, and ending on the date six
(6) months immediately
8
following, the effective date of any registration statement pertaining to
securities of the Company (other than a registration of securities in a Rule 145
transaction or with respect to an employee benefit plan), provided that the
Company is actively employing in good faith all reasonable efforts to cause such
registration statement to become effective; or
(iii) if the Company shall furnish to such Holder or Holders a
certificate signed by the Chief Executive Officer of the Company stating that in
the good faith judgment of the Chief Executive Office it would be seriously
detrimental to the Company or its stockholders for registration statements to be
filed in the near future, then the Company's obligation to use its best efforts
to file a registration statement shall be deferred for a period not to exceed
ninety (90) days from the receipt of the request to file such registration
statement by such Holder or Holders, provided that the Company may not exercise
this deferral right more than once per twelve (12) month period.
6.4 Limitations On Subsequent Registration Rights. From and after the
Closing Date, the Company shall not enter into any agreement granting any holder
or prospective holder of any securities of the Company registration rights with
respect to such securities that are superior to the rights granted to the
Purchasers hereunder without the written consent of the Holders of a majority of
the Registrable Securities then outstanding.
6.5 Expenses Of Registration. All Registration Expenses, other than
underwriting discounts and commissions and stock transfer taxes, but including
the fees and expenses of one counsel which shall collectively represent the
selling stockholders, shall be borne by the Company.
6.6 Registration Procedures. In the case of each registration,
qualification or compliance effected by the Company pursuant to this Agreement,
the Company will keep each Holder advised in writing as to the initiation of
each registration, qualification and compliance and as to the completion
thereof. The Company will:
(a) Prepare and file with the Commission a registration statement
with respect to such securities and use its best efforts to cause such
registration statement to become and remain effective for at least one hundred
twenty (120) days or until the distribution described in the registration
statement has been completed, whichever first occurs;
(b) Prepare and file with the Commission such amendments and
supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the
provisions of the Act with respect to the disposition of all securities covered
by such registration statement;
(c) Furnish to the Holders participating in such registration and to
the underwriters of the securities being registered such reasonable number of
copies of the registration statement, preliminary prospectus, final prospectus
and such other documents as such underwriters may reasonably request in order to
facilitate the public offering of such securities;
(d) Use best efforts to register and qualify the securities covered
by such registration statement under such other securities or Blue Sky laws of
such jurisdictions as shall
9
be reasonably requested by the Holders; provided that the Company shall not be
required in connection therewith or as a condition thereto to qualify to do
business or to file a general consent to service of process in any such states
or jurisdictions;
(e) In the event of any underwritten public offering, enter into and
perform its obligations under an underwriting agreement, in usual and customary
form, with the managing underwriter of such offering;
(f) Notify each Holder of Registrable Securities covered by such
registration statement at any time when a prospectus relating thereto is
required to be delivered under the Act or the happening of any event as a result
of which the prospectus included in such registration statement, as then in
effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading in the light of the circumstances then existing;
(g) Cause all such Registrable Securities registered pursuant
hereunder to be listed on each securities exchange on which similar securities
issued by the Company are then listed; and
(h) Provide a transfer agent and registrar for all Registrable
Securities registered pursuant hereunder and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such
registration.
6.7 Indemnification.
(a) The Company will indemnify each Holder, each of such Holder's
officers and directors and partners, and each person controlling such Holder
within the meaning of Section 15 of the Securities Act, with respect to which
registration, qualification or compliance has been effected pursuant to this
Agreement, and each underwriter, if any, and each person who controls any
underwriter within the meaning of Section 15 of the Securities Act, against all
expenses, claims, losses, damages or liabilities (or actions in respect
thereof), including any of the foregoing incurred in settlement of any
litigation, commenced or threatened, arising out of or based on any untrue
statement (or alleged untrue statement) of a material fact contained in any
registration statement, prospectus, offering circular or other document, or any
amendment or supplement thereto, incident to any such registration,
qualification or compliance, or based on any commission (or alleged omission) to
state therein a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances in which they were made,
not misleading, or any violation by the Company of the Securities Act of 1933,
the Securities Exchange Act of 1934, state securities law or any rule or
regulation promulgated under such laws applicable to the Company in connection
with any such registration, qualification or compliance, and the Company will
reimburse each such Holder, each of such Holder's officers and directors, and
each person controlling such Holder, each such underwriter and each person who
controls any such underwriter, for any legal and any other expenses reasonably
incurred, as such expenses are incurred, in connection with investigating,
preparing or defending of any such claim, loss, damage, liability or action,
provided that the Company will not be liable in any such case to the extent that
any such claim, loss, damage, liability or expense arises out of or is based on
any untrue statement or omission or alleged untrue statement or
10
omission, made in reliance upon and in conformity with written information
furnished to the Company by an instrument duly executed by such Holder,
controlling person or underwriter and stated to be specifically for use therein;
provided, however, that the foregoing indemnity agreement is subject to the
condition that, insofar as it relates to any such untrue statement, alleged
untrue statement, omission or alleged omission made in a preliminary prospectus
on file with the Commission at the time the registration statement becomes
effective or the amended prospectus filed with the Commission pursuant to Rule
424(b) (the "Final Prospectus"), such indemnity agreement shall not inure to the
benefit of any underwriter or any Holder, if there is no underwriter, if a copy
of the Final Prospectus was not furnished to the person asserting the loss,
liability, claim or damage at or prior to the time such action is required by
the Securities Act, and if the Final Prospectus would have cured the defect
giving rise to the loss, liability, claim or damage.
(b) Each Holder will, if Registrable Securities held by such Holder
are included in the securities as to which such registration, qualification or
compliance is being effected, indemnify the Company, each of its directors and
officers, each underwriter, if any, of the Company's securities covered by such
a registration statement, each person who controls the Company or such
underwriter within the meaning of Section 15 of the Securities Act, and each
other such Holder, each of such Holder's officers and directors and each person
controlling such Holder within the meaning of Section 15 of the Securities Act,
against all claims, losses, damages and liabilities (or actions in respect
thereof) arising out of or based on any untrue statement (or alleged untrue
statement) of a material fact contained in any such registration statement,
prospectus, offering circular or other document, or any omission (or alleged
omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse the
Company, such Holders, such directors, officers, persons, underwriters or
control persons for any legal or any other expenses reasonably incurred, as such
expenses are incurred, in connection with investigating or defending any such
claim, loss, damage, liability or action, in each case to the extent, but only
to the extent, that such untrue statement (or alleged untrue statement) or
omission (or alleged omission) is made in such registration statement,
prospectus, offering circular or other document in reliance upon and in
conformity with written information furnished to the Company by an instrument
duly executed by such Holder and stated to be specifically for use therein.
Notwithstanding the foregoing, the liability of each Holder under this
subsection 6.7(b) shall be limited to such Holder's net proceeds received for
the shares sold by such Holder.
(c) Each party entitled to indemnification under this Section 6.7
(the "Indemnified Party") shall give notice to the party required to provide
indemnification (the "Indemnifying Party") promptly after such Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of any such claim or any
litigation resulting therefrom, provided that counsel for the Indemnifying
Party, who shall conduct the defense of such claim or litigation, shall be
approved by the Indemnified Party (whose approval shall not unreasonably be
withheld), and the Indemnified Party may participate in such defense at such
party's expense, and provided further that the failure of any Indemnified Party
to give notice as provided herein shall not relieve the Indemnifying Party of
its obligations under this Agreement unless the failure to give such notice is
materially prejudicial to an Indemnifying Party's ability to defend such action
and provided further, that the Indemnifying Party shall not assume the defense
for matters as to which there is
11
a conflict of interest or separate and different defenses. No Indemnifying
Party, in the defense of any such claim or litigation, shall, except with the
consent of each Indemnified Party, consent to entry of any judgment or enter
into any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such Indemnified Party of a release from
all liability in respect to such claim or litigation.
6.8 Information By Holder. The Holder or Holders of Registrable
Securities included in any registration shall furnish to the Company such
information regarding such Holder or Holders, the Registrable Securities held by
them and the distribution proposed by such Holder or Holders as the Company may
request in writing and as shall be required in connection with any registration,
qualification or compliance referred to in this Agreement.
6.9 Rule 144 Reporting. With a view to making available the benefits of
certain rules and regulations of the Commission which may at any time permit the
sale of the Restricted Securities to the public without registration, after such
time as a public market exists for the Common Stock of the Company, the Company
agrees to use all reasonable efforts to:
(a) Make and keep public information available, as those terms are
understood and defined in Rule 144 under the Securities Act, at all times after
the effective date that the Company becomes subject to the reporting
requirements of the Securities Act or the Securities Exchange Act of 1934, as
amended;
(b) File with the Commission in a timely manner all reports and other
documents required of the Company under the Securities Act and the Securities
Exchange Act of 1934, as amended (at any time after it has become subject to
such reporting requirements); and
(c) So long as the Purchaser owns any Restricted Securities to
furnish to the Purchaser forthwith upon request a written statement by the
Company as to its compliance with the reporting requirements of said Rule 144
(at any time after ninety (90) days after the effective date of the first
registration statement filed by the Company for an offering of its securities to
the general public), and of the Securities Act and the Securities Exchange Act
of 1934 (at any time after it has become subject to such reporting
requirements), a copy of the most recent annual or quarterly report of the
Company, and such other reports and documents of the Company and other
information in the possession of or reasonably obtainable by the Company as the
Purchaser may reasonably request in availing itself of any rule or regulation of
the Commission allowing the Purchaser to sell any such securities without
registration.
6.10 Transfer Of Registration Rights. The rights to cause the Company to
register securities granted to the Purchasers under Sections 6.1, 6.2 and 6.3
may be assigned to a transferee or assignee in connection with any transfer or
assignment of Registrable Securities by the Purchaser pro-vided that: (i) such
transfer may otherwise be effected in accordance with applicable securities
laws, and (ii) such transferee agrees to be bound by the provisions of this
Agreement. Notwithstanding the foregoing, the rights to cause the Company to
register securities may be assigned to any constituent partner or member or
retired partner or member of a Purchaser which is a partnership or limited
liability company, or an affiliate of a Purchaser which is a corporation, or a
family member or trust for the benefit of a Purchaser who is an individual, or
to any holder of at least ten percent (10%) of the then outstanding Registrable
12
Securities (including Conversion Stock) provided written notice thereof is
promptly given to the Company and the transferee agrees to be bound by the
provisions of this Agreement.
6.11 Termination of Registration Rights. The rights granted pursuant to
Sections 6.1, 6.2 and 6.3 of this Agreement shall terminate at the earlier of:
(i) five (5) years after the date of the closing of the Company's initial public
offering, or (ii) with respect to a Holder, at such time as the Holder is able
to sell all of such Holder's shares pursuant to Rule 144 promulgated under the
Securities Act, during any three (3) month period provided that the Company is
subject to the reporting requirements of the Securities Exchange Act of 1934, as
amended.
7. Standoff Agreement. Each Holder hereby agrees that it will not, without
the prior written consent of the managing underwriter, during the period
commencing on the date of the final prospectus relating to the Company's initial
public offering and ending on the date specified by the Company and the managing
underwriter (such period not to exceed one hundred eighty (180) days): (i) lend,
offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to
purchase, or otherwise transfer or dispose of, directly or indirectly, any
shares of Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock (whether such shares or any such securities are
then owned by the Holder or are thereafter acquired), or (ii) enter into any
swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of the Common Stock, whether any such
transaction described in clause (i) or (ii) above is to be settled by delivery
of Common Stock or such other securities, in cash or otherwise. The foregoing
provisions of this Section shall apply only to the Company's initial public
offering of equity securities, shall not apply to the sale of any shares to an
underwriter pursuant to an underwriting agreement and shall only be applicable
to the Holders if all officers and directors and greater than five percent (5%)
stockholders of the Company enter into similar agreements. The underwriters in
connection with the Company's initial public offering are intended third party
beneficiaries of this Section and shall have the right, power and authority to
enforce the provisions hereof as though they were a party hereto. The Holders
and ▇▇▇▇ ▇. ▇▇▇▇, ▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇ agree that
the Company may instruct its transfer agent to place stop-transfer notations in
its records to enforce the provisions of this Section 7.
8. Right Of First Refusal By Purchasers.
8.1 Grant. The Company hereby grants to each of the Purchasers the right
of first refusal to purchase, pro rata, all or any part of the New Securities
(as defined in Section 8.2) which the Company may from time to time propose to
sell and issue. For purposes of this Agreement, a Purchaser's pro rata share is
the ratio of the number of shares (on an as converted basis) of Registrable
Securities purchased pursuant to the Purchase Agreements and Common Stock
(collectively, the "Shares") held by such Purchaser to the total number of
shares of Common Stock outstanding or issuable upon the conversion of any
convertible securities to acquire Common Stock. If for any reason, a Purchaser
should fail to exercise its right of first refusal provided in this Section 8,
its pro rata share of New Securities, as defined hereinafter, may be purchased
by the other Purchasers exercising such right in proportion, as nearly as
practicable, to the ratio of the number of Shares held by any such Purchaser to
the total number
13
of Shares held by all Purchasers exercising such right. This right of first
refusal shall be subject to the following provisions:
8.2 Definition. "New Securities" shall mean any equity security of the
Company, whether now authorized or not, and rights, options, or warrants to
purchase said equity security, and securities of any type whatsoever that are,
or may become convertible into or exercisable for said equity security; provided
that "New Securities" does not include: (i) Series A Preferred Stock purchased
pursuant to the Series A Purchase Agreement, including Common Stock issuable
upon conversion of such Series A Preferred Stock; (ii) Series B Preferred Stock
purchased pursuant to the Series B Purchase Agreement, including Common Stock
issuable upon conversion of such Series B Preferred Stock; (iii) any Series C
Preferred Stock that may be issued after July 31, 1997, including Common Stock
issuable upon conversion of such Series C Preferred Stock; (iv) Series D
Preferred Stock and warrant to purchase such Series D Preferred Stock purchased
pursuant to the Series D Purchase Agreement, including Common Stock issuable
upon conversion of such Series D Preferred Stock; (v) Series E Preferred Stock
and warrants to purchase such Series E Preferred Stock purchased pursuant to the
Series E Purchase Agreement, including Common Stock issuable upon conversion of
such Series E Preferred Stock; (vi) Series F Preferred Stock purchased pursuant
to the Series F Purchase Agreement, including Common Stock issuable upon
conversion of such Series F Preferred Stock (vii) securities offered to the
public generally pursuant to a registration statement, or under Regulation A, of
the Securities Act; (viii) securities issued pursuant to the acquisition of
another business entity by the Company by merger, purchase of substantially all
of the assets of such entity, or other reorganization; (ix) shares of the
Company's Common Stock issued pursuant to any arrangement approved by the Board
of Directors to employees, officers, and directors of, or consultants or other
persons performing services for, the Company; (x) shares of the Company's Common
Stock or Preferred Stock issued in connection with any stock split, stock
dividend, or recapitalization of the Company; (xi) warrants to purchase an
aggregate of 5,692 shares of Common Stock issued to Imparial Bank, including any
Common Stock issued upon exercise or conversion thereof; (xii) a warrant to
purchase Common Stock issued to ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, including any Common Stock
issued upon exercise or conversion thereof; or (xiii) stock issued pursuant to
any rights or agreements including without limitation convertible securities,
options and warrants, provided that the rights of first refusal established by
this Section 8 apply with respect to the initial sale or grant by the Company of
such rights or agreements.
8.3 Notices. In the event the Company proposes to undertake an issuance
of New Securities, it shall give each Purchaser written notice (the "Notice") of
its intention, describing the type of New Securities, the price, and the
principal terms upon which the Company proposes to issue the same, and the
minimum number of New Securities that the Purchaser will be eligible to purchase
pursuant to this Section 8. Each Purchaser shall have fifteen (15) days from the
delivery date of any Notice to agree to purchase up to the Purchaser's pro rata
share of such New Securities for the price and upon the terms specified in the
Notice by giving written notice to the Company and stating therein the quantity
of New Securities to be purchased and the name of the proposed purchasers, if
known; provided, however, that in the event the Notice provides for payment for
such New Securities other than in cash, each Purchaser shall have the option of
paying for the New Securities by the discounted cash equivalent of the
consideration described in the Notice as set forth in the Notice and as
determined in good faith by the Board of Directors. If any Purchaser fails at
any time to exercise his or her right hereunder to purchase all of the New
14
Securities to which he or she is then entitled, the Company shall promptly
deliver a notice to all Purchasers stating the number of New Securities with
respect to which the Right of Refusal is not being exercised and each
Purchaser's pro rata share of such New Securities, and the other Purchasers
exercising their rights under this Section may, within five (5) days from the
date on which the Company delivers such a notice, agree to purchase pro rata all
of such New Securities.
8.4 Failure to Exercise Right. In the event Purchasers fail to exercise
the right of first refusal as to all of the New Securities pursuant to Section
8, the Company shall have ninety (90) days after the last date on which
Purchasers' right to purchase lapsed to sell or enter into an agreement
(pursuant to which the sale of New Securities covered thereby shall be closed,
if at all, within ninety (90) days from the date of said agreement) to sell the
New Securities respecting which the Purchasers' option was not exercised, at or
above the price and upon terms not materially more favorable to the purchasers
of such securities than specified in the initial Notice given in connection with
such sale. In the event the Company has not sold the New Securities or entered
into an agreement to sell the New Securities within said ninety (90) day period
(or sold and issued New Securities in accordance with the foregoing within
ninety (90) days from the date of said agreement), the Company shall not
thereafter issue or sell any New Securities without first offering such
securities to the Purchasers in the manner provided above.
8.5 Termination. The right of first refusal granted under this Section
shall expire as to all of the Purchasers upon the closing of a firm commitment
underwritten public offering pursuant to an effective registration statement on
Form S-1 or any successor form under the Securities Act of 1933, as amended,
covering the offer and sale of Common Stock for the account of the Company to
the public at a price per share (prior to underwriter commissions and offering
expenses) of not less than twenty dollars ($20.00) per share (appropriately
adjusted for any recapitalizations, stock splits, stock combinations, stock
dividends and the like) which results in aggregate net cash proceeds to the
Company in excess of twenty million dollars ($20,000,000).
8.6 Assignment. The right of first refusal granted under this Section may
not be assigned to a transferee of less than fifty thousand (50,000) shares of
Preferred Stock or Conversion Stock or all of the Preferred Stock or Conversion
Stock previously held by the transferor; provided, however, that this right of
first refusal may be assigned by any Purchaser to any wholly-owned subsidiary or
constituent partner or member, retired partner or member or estate of any
constituent or retired partner or member thereof, to any other Purchaser or to
any affiliated entity of a Purchaser.
9. Information, Inspection, And Management Rights.
9.1 Rights.
(a) As soon as practicable after the end of each fiscal year
beginning with fiscal year 1995, and in any event within ninety (90) days
thereafter, the Company will mail to each Purchaser who continues to hold at
least ten percent (10%) of the Registrable Securities purchased pursuant to the
Series A Purchase Agreement, at least ten percent (10%) of the Registrable
Securities purchased pursuant to the Series B Purchase Agreement, at least ten
percent (10%) of the Registrable Securities purchased pursuant to the Series C
Purchase
15
Agreement, at least ten percent (10%) of the Registrable Securities purchased
pursuant to the Series D Purchase Agreement, at least ten percent (10%) of the
Registrable Securities purchased pursuant to the Series E Purchase Agreement or
at least ten percent (10%) of the Registrable Securities purchased pursuant to
the Series F Purchase Agreement, the audited consolidated financial statements
for the Company and its consolidated subsidiaries for such year, prepared in
accordance with generally accepted accounting principles.
(b) As soon as practicable after the end of each month, and in any
event within thirty (30) days thereafter, the Company will mail to each
Purchaser who continues to hold at least ten percent (10%) of the Registrable
Securities purchased pursuant to the Series A Purchase Agreement, at least ten
percent (10%) of the Registrable Securities purchased pursuant to the Series B
Purchase Agreement, at least ten percent (10%) of the Registrable Securities
purchased pursuant to the Series C Purchase Agreement, at least ten percent
(10%) of the Registrable Securities purchased pursuant to the Series D Purchase
Agreement, at least ten percent (10%) of the Registrable Securities purchased
pursuant to the Series E Purchase Agreement or at least ten percent (10%) of the
Registrable Securities purchased pursuant to the Series F Purchase Agreement, a
consolidated balance sheet and statement of operations (that would include a
profit and loss statement) for the Company and its consolidated subsidiaries for
such month, prepared in accordance with generally accepted accounting
principles.
(c) As soon as practicable after the end of each fiscal quarter and
in any event within forty-five (45) days thereafter, the Company will mail to
each Purchaser who continues to hold at least ten percent (10%) of the
Registrable Securities purchased pursuant to the Series A Purchase Agreement, at
least ten percent (10%) of the Registrable Securities purchased pursuant to the
Series B Purchase Agreement, at least ten percent (10%) of the Registrable
Securities purchased pursuant to the Series C Purchase Agreement, at least ten
percent (10%) of the Registrable Securities purchased pursuant to the Series D
Purchase Agreement, at least ten percent (10%) of the Registrable Securities
purchased pursuant to the Series E Purchase Agreement or at least ten percent
(10%) of the Registrable Securities purchased pursuant to the Series F Purchase
Agreement, a quarterly budget and a narrative report prepared by the Company's
President explaining any deviations from the previous budget.
(d) So long as a Purchaser holds at least ten percent (10%) of the
Registrable Securities purchased pursuant to the Series A Purchase Agreement, at
least ten percent (10%) of the Registrable Securities purchased pursuant to the
Series B Purchase Agreement, at least ten percent (10%) of the Registrable
Securities purchased pursuant to the Series C Purchase Agreement, at least ten
percent (10%) of the Registrable Securities purchased pursuant to the Series D
Purchase Agreement, at least ten percent (10%) of the Registrable Securities
purchased pursuant to the Series E Purchase Agreement or at least ten percent
(10%) of the Registrable Securities purchased pursuant to the Series F Purchase
Agreement, such Purchaser or its representative shall have the right to: (i)
consult with and advise management of the Company on significant business
issues, including management's proposed annual operating plans, (ii) meet with
management of the Company regularly during each year at the Company's facilities
at mutually agreeable times for such consultation and advice and to review
progress in achieving said plans, (iii) examine the books and records of the
Company and inspect its facilities and request information at reasonable times
and intervals concerning the general status of the Company's financial condition
and operations, provided that access to highly confidential
16
proprietary information and facilities need not be provided, and (iv) if the
Purchaser is not represented on the Company's Board of Directors, the Company
shall invite a representative of the Purchaser to attend all meetings of its
Board of Directors in a nonvoting observer capacity, and in this respect shall
give such representative copies of all notices, minutes, consents, and other
material that it provides to its directors; provided however, that the Company
reserves the right to exclude such representative from access to any material or
meeting or portion thereof if the Company believes upon advice of counsel that
such exclusion is reasonably necessary to preserve the attorney-client
privilege, to protect highly confidential proprietary information or for other
similar reasons. Such representative may participate in discussion of matters
brought to the Board.
9.2 Assignment of Information and Inspection Rights. The rights granted
pursuant to Section 9.1 may not be assigned or otherwise conveyed by any
Purchaser or by any subsequent transferee of any such rights; provided, however,
that such Purchaser, after giving notice to the Company in a timely manner, and
subject to the Company's right to prohibit the transfer of such rights to an
industry recognized competitor of the Company, may assign the rights granted
pursuant to Section 9.1 (other than the rights set forth in Section 9.1(d),
which may not be assigned) to any transferee who acquires not less than fifty
thousand (50,000) shares of Preferred Stock or Common Stock issued upon
conversion of such number of shares of Preferred Stock, or a combination
thereof.
9.3 Confidentiality. Unless otherwise consented to in writing by the
Company, the Purchaser or its assignee agree, and any representative of such
purchaser or its assignee will agree, to hold in confidence and trust and not
use or disclose any confidential information provided to or learned by it in
connection with the rights granted in Sections 9.1 and 9.2.
9.4 Termination of Covenants. The obligations of the Company set forth in
Sections 9.1 and 9.2 shall terminate and be of no further force or effect upon
the earlier of: (i) the closing of an underwritten public offering pursuant to
an effective registration statement under the Securities Act, or (ii) at such
time the Company is required to file reports pursuant to Section 13 of the
Securities Exchange Act of 1934, as amended. The confidentiality provisions set
forth in Section 9.3 survive any such termination.
10. Voting Of A Director. The Company and the Holders agree to use their best
efforts (including appropriate nominations of individuals for director and
voting of shares of voting stock) to ensure that the director to be selected
pursuant to the Company's Certificate of Incorporation by the holders of Common
Stock, Series A Preferred Stock, Series B Preferred Stock, Series C Preferred
Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred
Stock, voting together as a class on an as converted basis, shall be acceptable
to the directors elected by the holders of Series A Preferred Stock, Series B
Preferred Stock, Series C Preferred Stock and Series D Preferred Stock (voting
together as a single class on an as-converted-to-Common Stock basis) and the
director elected by holders of Series E Preferred Stock (voting as a single
class) as well as the directors elected by the Common Stock (voting as a single
class).
11. Amendment. Any provision of this Agreement may be amended or the
observance thereof may be waived (either generally or in a particular instance
and either retroactively or
17
prospectively), only with the written consent of the Company and the holders of
not less than a majority of the Registrable Securities then outstanding. Any
amendment or waiver effected in accordance with this Section 11 shall be binding
upon each Purchaser and each Holder of Registrable Securities at the time
outstanding (including securities into which such securities are convertible),
each future holder of all such securities, and the Company.
12. Governing Law. This Agreement and the legal relations between the parties
arising hereunder shall be governed by and interpreted in accordance with the
laws of the State of California, without respect to rules concerning the
conflict of laws which would otherwise require application of the substantive
law of another jurisdiction. The parties hereto agree to submit to the
jurisdiction of the federal and state courts of the State of California matters
with respect to the breach or interpretation of this Agreement or the
enforcement of any and all rights, duties, liabilities, obligations, powers, and
other relations between the parties arising under this Agreement.
13. Entire Agreement. This Agreement constitutes the full and entire
understanding and agreement between the parties regarding the matters set forth
herein. Except as otherwise expressly provided herein, the provisions hereof
shall inure to the benefit of, and be binding upon the successors, assigns,
heirs, executors and administrators of the parties hereto.
14. Notices. All notices and other communications required or permitted
hereunder shall be in writing and shall be deemed effectively given upon
personal delivery to the party to be notified or three (3) days after deposit
with the United States mail, by registered or certified mail, postage prepaid,
addressed: (a) if to a Purchaser, at such Purchaser's address as set forth on
the Schedule of Purchasers attached hereto, or at such other address as such
Purchaser shall have furnished to the Company in writing in accordance with this
Section 14, (b) if to any other holder of Conversion Stock, at such address as
such holder shall have furnished the Company in writing in accordance with this
Section 14, or, until any such holder so furnishes an address to the Company,
then to and at the address of the last holder thereof who has so furnished an
address to the Company, or (c) if to the Company, at its principal office.
15. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.
[THIS SPACE INTENTIONALLY LEFT BLANK]
18
The foregoing agreement is hereby executed as of the date first above
written.
Company:
LXN Corporation
▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
By:______________________________________
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, President
19
"PURCHASERS"
_________________________________________
▇▇▇▇ ▇. ▇▇▇▇
▇▇▇▇ ▇. ▇▇▇▇▇
LESOTO TRUST
By: _____________________________________
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, Trustee
▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ TRUST
By: _____________________________________
▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇,
Trustee
D&A PARTNERS
By: _____________________________________
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
Title: __________________________________
_________________________________________
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
_________________________________________
▇▇▇▇▇▇▇▇ ▇▇▇▇▇
20
SINGH TRUST, UDT April 17, 1986
By: _____________________________________
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, Trustee
By: _____________________________________
▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, Trustee
_________________________________________
▇▇▇▇▇▇ ▇. ▇▇▇▇▇
_________________________________________
▇▇▇ ▇. ▇▇▇▇▇
_________________________________________
▇▇▇▇▇▇ ▇. ▇▇▇▇▇
_________________________________________
DIAGNOSTIC SOLUTIONS, INC.
By: _____________________________________
Name: ___________________________________
Title: __________________________________
▇▇▇▇▇ ENTERPRISES, INC.
By: _____________________________________
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
Title: __________________________________
21
▇▇▇▇▇▇▇ 1988 REVOCABLE TRUST
By: _____________________________________
▇▇▇▇▇▇ ▇▇▇▇▇▇▇,
Trustee
ALTA V LIMITED PARTNERSHIP
By: ALTA V MANAGEMENT PARTNERS, L.P.
By: _____________________________________
Name: ___________________________________
Title: General Partner
CUSTOMS HOUSE PARTNERS
By: _____________________________________
Name: ___________________________________
Title: General Partner
▇▇▇▇▇▇ CAPITAL PARTNERS
▇▇▇▇▇▇ VENTURES
▇▇▇▇▇▇ INVESTORS
▇▇▇▇▇▇ INTERNATIONAL III, ▇.▇.
▇▇▇▇▇▇ CAPITAL PARTNERS II, ▇.▇.
▇▇▇▇▇▇ TECHNOLOGY VENTURES II, ▇.▇.
▇▇▇▇▇▇ - SIBC, L.P.
By: _____________________________________
Name: ___________________________________
Title: General Partner
22
_________________________________________
▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
MJT TRUST
By: _____________________________________
Name: ___________________________________
Title: Trustee
WS INVESTMENT COMPANY 95A
By: _____________________________________
Name: ___________________________________
Title: General Partner
ROVENT II LIMITED PARTNERSHIP
By: ADVENT INTERNATIONAL LIMITED
PARTNERSHIP,
General Partner
By: ADVENT INTERNATIONAL CORPORATION,
General Partner
By: _____________________________________
Name: ___________________________________
Title: __________________________________
23
ADVENT PERFORMANCE MATERIALS
LIMITED PARTNERSHIP
By: ADVENT INTERNATIONAL LIMITED
PARTNERSHIP, General Partner
By: ADVENT INTERNATIONAL CORPORATION,
General Partner
By: _____________________________________
ADVENT INTERNATIONAL INVESTORS II
LIMITED PARTNERSHIP
By: ADVENT INTERNATIONAL CORPORATION,
General Partner
By: _____________________________________
ADVENT PARTNERS LIMITED PARTNERSHIP
By: ADVENT INTERNATIONAL CORPORATION,
General Partner
By: _____________________________________
Name: ___________________________________
Title: __________________________________
_________________________________________
Dr. ▇▇▇▇▇▇ ▇▇
_________________________________________
▇▇▇▇▇ ▇▇▇▇▇▇
24
_________________________________________
▇▇▇▇▇▇ ▇▇▇▇▇▇
_________________________________________
Pierre ▇▇▇▇▇ ▇▇▇▇▇▇▇
_________________________________________
▇▇▇▇▇ ▇▇▇▇▇▇
_________________________________________
▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
_________________________________________
▇▇▇▇ ▇▇▇▇▇▇
_________________________________________
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
_________________________________________
▇▇▇▇ ▇▇▇▇▇▇▇ (Plan bygg Holdings AS)
_________________________________________
▇▇▇▇ ▇▇▇▇▇▇▇▇▇
BANCA DEL GOTTARDO
By: _____________________________________
Name: ___________________________________
Title: __________________________________
25
BIOTECHNOLOGY DEVELOPMENT FUND, L.P.
By: _____________________________________
Name: ___________________________________
Title: __________________________________
▇▇▇▇▇▇ INTERNATIONAL, LTD.
By: _____________________________________
Name: ___________________________________
Title: __________________________________
INVESTAR BURGEON VENTURE CAPITAL, INC.
By: _____________________________________
Name: ___________________________________
Title: __________________________________
INVESTAR DAYSPRING VENTURE CAPITAL, INC.
By: _____________________________________
Name: ___________________________________
Title: __________________________________
26
MICROLIFE INVESTMENT CORP.
By: _____________________________________
Name: ___________________________________
Title: __________________________________
_________________________________________
▇▇▇▇▇▇ ▇.▇. ▇▇▇▇
HOFUNG HOLDINGS, LTD.
By: _____________________________________
Name: ___________________________________
Title: __________________________________
MATON FUND I, L.P.
By: _____________________________________
Name: ___________________________________
Title: __________________________________
NIPPON INVESTMENT AND FINANCE CO., LTD.
By: _____________________________________
Name: ___________________________________
Title: __________________________________
27
INVESTMENT ENTERPRISE PARTNERSHIP
"NIFIOA"
By: _____________________________________
Name: ___________________________________
Title: __________________________________
INVESTMENT ENTERPRISE PARTNERSHIP
"NIFIOB"
By: _____________________________________
Name: ___________________________________
Title: __________________________________
_________________________________________
Arthur T.C. Au
CGRM Partners,
a Wisconsin General Partnership
Name:____________________________________
Title:___________________________________
MedVenture Associates II
By:______________________________________
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇-▇▇▇▇▇
Managing Member of MedVenture
Associates II
Management Co., L.L.C., the General
Partner of MedVenture Associates II
28
Premier Medical Partner Fund, L.P.
By: Premier Capital Corporation
its General Partner
By:______________________________________
Name:____________________________________
Title:___________________________________
_________________________________________
▇▇▇▇▇▇ Von Matt
_________________________________________
▇▇▇▇▇▇ ▇▇▇▇▇▇
_________________________________________
Fisca Finanz Ag
_________________________________________
Xaver Andermatt
_________________________________________
▇▇▇▇▇▇ ▇▇▇▇▇▇▇
Child Health Investment Corporation
By:______________________________________
▇▇▇▇▇ ▇▇▇▇▇▇▇
Senior Vice President and CFO
_________________________________________
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
_________________________________________
▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
29
_________________________________________
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
_________________________________________
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
BB BIOVENTURES L.P.
By: BB BIOVENTURES L.P., its General Partner
By: BB BIOVENTURES, N.V., its General Partner
By:___________________________________________
Name: ▇▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
Title Managing Director
MPM BIOVENTURES PARALLEL FUND, L.P.
By:___________________________________________
Name: ▇▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
Title Manager
MPM ASSET MANAGEMENT INVESTORS 1999 LLC
By:___________________________________________
Name: ▇▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
Title Manager
TDF MANAGEMENT PTE LTD.
By: __________________________________________
Name: ________________________________________
Title: _______________________________________
30
VENTANA
By: _____________________________________
Name: ___________________________________
Title: _________________________________
VICTORY VENTURES LLC
By: _____________________________________
Name: ___________________________________
Title: __________________________________
PARIBAS
By: _____________________________________
Name: ___________________________________
Title: _________________________________
DRW VENTURE PARTNERS LP
By: ▇▇▇▇ ▇▇▇▇▇▇▇ Corporation
Its: General Partner
By: _____________________________________
Its: ____________________________________
[▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇]
By: _____________________________________
Its: ____________________________________
31
_________________________________________
▇▇▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇▇ INTERNATIONAL LTD
By: _____________________________________
Its: ____________________________________
_________________________________________
HA ▇▇▇ ▇▇▇ ▇▇▇▇▇
[Signature Page to Sixth Amended and Restated Registration Rights Agreement]
32
EXHIBIT A
---------
SERIES A PURCHASERS
Number of
Series A Purchasers Series A Shares
------------------- ---------------
Alta V Limited Partnership 214,413
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇ ▇▇▇▇▇
▇▇▇▇ ▇. ▇▇▇▇ 6,667
▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇
▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Customs House Partners 2,254
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: Guy ▇▇▇▇▇
▇▇▇▇▇ Enterprises, Inc. 11,333
▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
▇▇▇ ▇. ▇▇▇▇▇ 6,000
▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇ 6,000
▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
LeSoTo Trust 10,071
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ Trustee
Stanwood & Price
▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
A-1
Number of
Series A Purchasers Series A Shares
------------------- ---------------
▇▇▇▇▇▇▇ 1988 Revocable Trust, 33,333
▇▇▇▇▇▇ ▇▇▇▇▇▇▇ Trustee
c/o Sequoia Capital
▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇ ▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
MJT Trust 8022
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, Trustee
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ Trust 8021
▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇, Trustee
▇▇▇▇▇ ▇▇▇ ▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ Capital Partners 20,000
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Ventures 28,622
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Investors 40,000
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ International III, C.V. 40,000
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
A-2
Number of
Series A Purchasers Series A Shares
------------------- ---------------
▇▇▇▇▇▇ Capital Partners II, L.P. 60,000
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Technology Ventures II, L.P. 12,002
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ 7,333
▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Singh Trust UDT April 17, 1986 10,000
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ and ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇ Trustees
▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇ ▇▇▇▇▇ 6,000
▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇ ▇. ▇▇▇▇▇ 13,263
c/o MedVenture Associates ------
▇ ▇▇▇▇▇▇ ▇▇▇, ▇▇▇▇. ▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
TOTAL: 543,334
A-3
EXHIBIT B
---------
SERIES B PURCHASERS
Number of
Series B Purchasers Series B Shares
------------------- ---------------
LeSoTo Trust 7,000
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, Trustee
Stanwood & Price
Court House Plaza
▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ Trust 13,437
▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇, Trustee
▇▇▇▇▇ ▇▇▇ ▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
D&A Partners 1,750
c/o ▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇. ▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ 7,000
▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ 1988 Revocable Trust 21,800
▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Trustee
c/o Sequoia Capital
▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇ ▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ 9,000
▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇.
▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
B-1
Number of
Series B Purchasers Series B Shares
------------------- ---------------
MJT Trust 5,187
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇,
Trustee
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇-▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ Capital Partners 13,000
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Ventures 17,924
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Investors 26,000
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ International III, C.V. 26,000
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Capital Partners II, L.P. 39,000
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Technology Ventures II, L.P. 7,802
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
B-2
Number of
Series B Purchasers Series B Shares
------------------- ---------------
Alta V Limited Partnership 138,643
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇ ▇▇▇▇▇
Customs House Partners 1,457
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇ ▇▇▇▇▇
Rovent II Limited Partnership 105,333
c/o Advent International
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Advent Performance Materials Limited Partnership 52,667
c/o Advent International
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Advent International Investors II Limited Partnership 1,000
c/o Advent International
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Advent International 1,000
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
WS Investment Company 95A 5,000
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ -----
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
TOTAL: 500,000
B-3
EXHIBIT C
---------
SERIES C PURCHASERS
Number of Series
Series C Purchasers C Shares
------------------- --------
Alta V Limited Partnership 29,688
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇ ▇▇▇▇▇
Customs House Partners 312
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇ ▇▇▇▇▇
Rovent II Limited Partnership 9,938
c/o Advent International
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Advent Performance Materials Limited 4,968
Partnership
c/o Advent International
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Advent Partners Limited Partnership 94
c/o Advent International
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Banca del Gottardo 304,000
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ ▇
▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇ 5,000
▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
Knonau, ZH 8934
C-1
Number of Series
Series C Purchasers C Shares
------------------- --------
▇▇▇▇▇▇ ▇▇▇▇▇▇ 10,000
▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇
▇▇▇▇▇▇▇▇▇▇▇
Luzern 6005
Pierre ▇▇▇▇▇ ▇▇▇▇▇▇▇ 30,000
▇▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇
▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇ 20,000
▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇
▇▇▇▇▇▇▇▇▇▇▇
Basserdorf 8303
▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ 1,000
▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇ 5,000
▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇ ▇
▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇/▇▇▇▇▇▇▇▇ (▇▇) ▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ 25,000
▇▇▇▇▇▇▇▇▇▇ ▇▇
▇▇▇▇▇▇
Asker 1370
Planbygg Holdings AS 5,000
▇▇▇▇ ▇▇▇▇▇▇▇
Billingstadsletta 91
Norway
Billingstad 1361
TDF Management PTE Ltd. 100,000
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇. #▇▇-▇▇/▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Science Park II
▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇
Attn: Dr. ▇▇▇▇▇▇ ▇▇
C-2
Number of Series
Series C Purchasers C Shares
------------------- --------
▇▇▇▇ ▇▇▇▇▇▇▇▇▇
c/o Prospectiva Investments 16,200
▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇ ------
▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
TOTALS: 566,200
C-3
EXHIBIT D
---------
SERIES D PURCHASERS
Number of
Series D Purchasers Series D Shares
------------------- ---------------
Biotechnology Development Fund, L.P. 160,000
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ International, Ltd. 160,000
ChinaChem Golden Plaza
Top Floor
▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇▇
Investar Burgeon Venture Capital, Inc. 26,667
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Investar Dayspring Venture Capital, Inc. 53,333
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Microlife Investment Corp. 80,000
7Fm ▇▇▇ ▇▇ ▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇
R.O.C
▇▇▇▇▇▇ ▇.▇. ▇▇▇▇ 80,000
HoFung Holdings, Ltd. 16,000
▇.▇. ▇▇▇ ▇▇
1 Greenville Street
St. Helier
Jersey JE49PF
Channel Islands
Advent Partners Limited Partnership 251
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
D-1
Number of
Series D Purchasers Series D Shares
------------------- ---------------
Advent Performance Materials Limited Partnership 13,248
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Rovent II Limited Partnership 26,501
c/o Advent International
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Alta V Limited Partnership 79,168
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Customs House Partners 832
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
TDF Management PTE Ltd. 8,000
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇
#▇▇-▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇ Science Park II
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ Capital Partners 3,999
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇-SBIC, L.P. 25,588
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
D-2
Number of
Series D Purchasers Series D Shares
------------------- ---------------
▇▇▇▇▇▇ International III, C.V. 14,797
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Investors 14,797
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Technology Ventures II, L.P. 5,199
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Ventures 9,680
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇▇ 2,000
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇.
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇-▇▇▇▇ Yuan 40,000
▇▇▇▇▇▇ Von ▇▇▇▇ 1,600
c/o Emanuel Orbist
TEBOR Treuhand AG
dipl. Treuhandexperte
▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
D-3
Number of
Series D Purchasers Series D Shares
------------------- ---------------
▇▇▇▇▇▇ ▇▇▇▇▇▇ 2,500
c/o Emanuel Orbist
TEBOR Treuhand AG
dipl. Treuhandexperte
▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
Fisca Finanz Ag 4,000
c/o Emanuel Orbist
TEBOR Treuhand AG
dipl. Treuhandexperte
▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
Xaver Andermatt 4,000
c/o Emanuel Orbist
TEBOR Treuhand AG
dipl. Treuhandexperte
▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇ 1,000
c/o Emanuel Orbist
TEBOR Treuhand AG
dipl. Treuhandexperte
▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ 600
c/o Emanuel Orbist
TEBOR Treuhand AG
dipl. Treuhandexperte
▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ 600
c/o Emanuel Orbist
TEBOR Treuhand AG
dipl. Treuhandexperte
▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
D-4
Number of
Series D Purchasers Series D Shares
------------------- ---------------
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ 1,000
c/o Emanuel Orbist
TEBOR Treuhand AG
dipl. Treuhandexperte
▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ 1,000
c/o Emanuel Orbist
TEBOR Treuhand AG
dipl. Treuhandexperte
▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇
Maton Fund I, L.P. 80,000
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇, #▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇▇▇
Nippon Investment and Finance Co., Ltd. 8,000
First Market Tower
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Investment Enterprise Partnership "NIFIOA" 16,000
First Market Tower
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
Investment Enterprisei Partnership "NIFIOB" 16,000
First Market Tower
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
CGRM Investment Partnership 20,000
▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇ ▇▇▇▇▇▇
▇-▇
Number of
Series D Purchasers Series D Shares
------------------- ---------------
MedVenture Associates II 40,000
▇ ▇▇▇▇▇▇ ▇▇▇, ▇▇▇▇. ▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
ABN AMRO Bank (Shweiz) 5,600
▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇
▇.▇. ▇▇▇ ▇▇▇▇
▇▇ - ▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇
Attn: ▇▇▇▇ ▇▇▇▇▇▇▇
Dr. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ 300
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇.
▇▇▇▇▇ ▇
▇▇▇▇▇ ▇▇, ▇▇ ▇▇▇▇▇
Child Health Investment Corporation 20,000
▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇ ▇.▇. Au 16,000
Pun ▇▇▇▇▇ ▇▇▇▇
Suite 1203 Righful Center
Tak Hing St.
Kowloon,
Hong Kong
Premier Medical Partner Fund, L.P. 200,000
▇▇▇▇ ▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇
BioAsia LLC (Warrant to Purchase Shares
of Series D Preferred) 20,000
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇ ------
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇▇
TOTAL: 1,258,260
D-6
EXHIBIT E
---------
SERIES E PURCHASERS
Series E Purchasers Number of Series E Shares
------------------- -------------------------
BB BioVentures L.P. 502,673
▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, PhD
MPM BioVentures Parallel Fund, L.P 68,250
▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, PhD
MPM Asset Management Investors 6,000
1999, LLC
▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, PhD
▇▇▇▇ V Limited Partnership 57,093
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Customs House Partners 600
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ Capital Partners 3,075
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
E-1
Series E Purchasers Number of Series E Shares
------------------- -------------------------
▇▇▇▇▇▇-SBIC, L.P. 20,751
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Investors 7,690
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Technology Ventures II 4,181
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Ventures 7,325
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
Rovent II Limited Partnership 15,153
c/o Advent International
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Advent Partners Limited Partnership 144
c/o Advent International
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
Advent Performance Materials 7,575
Limited Partnership
▇/▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇▇
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ Moufflet
E-2
Series E Purchasers Number of Series E Shares
------------------- -------------------------
Premier Medical Partner Fund 21,276
▇▇▇▇ ▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇
Biotechnology Development Fund 17,021
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇▇
MedVenture Associates 19,230
▇ ▇▇▇▇▇▇ ▇▇▇, ▇▇▇▇. ▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Paribas 11,538
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Veron International, Ltd. 17,021
ChinaChem Golden Plaza
Top Floor
77 ▇▇▇▇ Road
TST East
Kowloon, Hong Kong
Attn: ▇▇▇▇▇▇ ▇▇▇▇▇
Child Health Investment Corporation 7,692
▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇ -----
▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
TOTAL: 794,288
E-3
EXHIBIT F
SERIES F PURCHASERS
Series F Purchasers Number of Series F Shares
------------------- -------------------------
BB BioVentures L.P. 61,671
▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, PhD
MPM BioVentures Parallel Fund L.P. 9,297
▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, PhD
MPM Asset Management Investor 1999 LLC 742
▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, PhD
▇▇▇▇ V Limited Partnership 35,343
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Customs House Partners 371
c/o Burr, Egan, Deleage & Co.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
F-1
Series F Purchasers Number of Series F Shares
------------------- -------------------------
▇▇▇▇▇▇-SBIC, L.P. 6,000
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Technology Ventures II 1,142
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇
[▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇] 35,714
[Address]
DRW Venture Partners LP 35,714
Attn: ▇▇▇▇ ▇▇▇▇▇▇ MS 54N2
▇▇ ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Veron International, Ltd. 144,234
ChinaChem Golden Plaza
Top Floor
▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇ International Limted 14,285
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇ 7,143
[address]
Ha ▇▇▇ ▇▇▇ ▇▇▇▇▇ 7,143
[address] -----
TOTAL: 358,799
F-2
An extra section break has been inserted above this paragraph. Do not delete
this section break if you plan to add text after the Table of
Contents/Authorities. Deleting this break will cause Table of
Contents/Authorities headers and footers to appear on any pages following the
Table of Contents/Authorities.
F-3
